Before every breakthrough in oncology, there’s phase I research — where innovation, teamwork, and patient trust come together.

In this episode, Dr. R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO, Vice President of Clinical Research and Executive Director of the Emory Clinical Research Office, joins hosts Ginger Blackmon, PharmD, and Maddy Floysand, PharmD, for an inside look at how early-phase clinical trials lay the groundwork for new cancer therapies.

Dr. Harvey, also Professor of Hematology/Medical Oncology and Pharmacology and Associate Dean for Clinical Research at Emory University, shares how phase I studies are evolving to balance discovery, safety, and patient care while expanding access beyond academic centers.

He talks about:

• How early-phase trials shape the future of oncology treatments
• Collaboration between academic and community sites to improve access and equity
• The vital role of pharmacists in study design, safety, and education
• How AI and data are changing trial design and patient matching
• Advice for clinicians and students interested in research careers

Dr. Harvey also reflects on the teamwork that drives meaningful progress and what continues to inspire him after decades of leading research that connects science to patient impact.